The LS132.1D9 (aka, 1D9) monoclonal antibody specifically recognizes C-C chemokine receptor type 2 (CCR2 or CC-CKR-2) which is also known as CD192, CKR2, CMKBR2, or Monocyte chemoattractant protein 1 receptor (MCP-1 Receptor or MCP-1-R). CCR2 (CD192) is a seven-transmembrane, G-protein-coupled, glycoprotein receptor that belongs to the beta chemokine receptor family. It is expressed on basophils, monocytes/macrophages, dendritic cells, activated T cells and B cells. CCR2 (CD192) serves as a receptor for Monocyte chemoattractant protein 1 (MCP-1/CCL2), MCP-2/CCL8, MCP-3/CCL7, and MCP-4/CCL13. CD192 exists in two forms, CD192A and CD192B. The two forms are derived from alternatively spliced variants of a single gene and differ at their intracellular C-terminal ends. CD192 plays an important role in inflammatory responses including monocytic infiltration of tissues associated with certain diseases, eg, atherosclerosis, rheumatoid arthritis, and tumors.
The antibody was conjugated to BD Horizon BUV615 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome with an Ex Max near 350 nm and an Em Max near 615 nm. BD Horizon Brilliant BUV615 can be excited by the ultraviolet laser (355 nm) and detected with a 610/20 filter and a 595 nm LP. Due to the excitation of the acceptor dye by the blue/yellow-green laser line, there may be significant spillover into channels detecting PE-CF594 like emissions (eg, 610/20-nm filter).